Bacopa Extract Research Wins Award

NOBLESVILLE, Ind.New clinical research on Bacopa monnieri (as Bacognize®, from Verdure Sciences) won the Best New Research Paper award at the 4th International Online Medical Conference 2011 (IOMC). According to IOMC, the award is given for technical quality, novelty and importance to the scientific field. The research is published in a recent issue of peer-reviewed International Journal of Collaborative Research on Internal Medicine and Public Health (2011; 3(4):285-293).

The open label, prospective, uncontrolled, non-randomized trial involved newly diagnosed patients of Alzheimers disease (AD) between 60-65 years of age, who took 300 mg of Bacognize orally twice a day for six months. Mini Mental State Examination Scale (MMSES) were recorded for all patients at both baseline and after the completion of the intervention period.

Among the 39 patients (mean age=65.23 years) who finished the trial, researchers found statistically significant improvements in various components of MMSES including orientation of time, place and person; attention; and in their language component in terms of reading, writing and comprehension. These patients also reported improvement in their quality of life, and decrease in the irritability and insomnia.

These results, especially when taken together with previous human trials on Bacognize®, adds to our level of understanding of how the Bacopa glycosides from this extract may work for people of different ages, and with different levels of cognitive health, said Blake Ebersole, technical director at Verdure.